As no mutation in MMR genes will be detected by germline testing, the tumor can wrongly be classified as LLS with low cancer risk, whereas it is known that carriers of an EPCAM deletion have a cumulative risk of CRC similar to carriers of MSH2 mutation [37]. Here, MSH2 is linked to neoplasm.